Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Condition(s):Prostate Adenocarcinoma; Prostate Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Last Updated:July 11, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Prostate Adenocarcinoma; Prostate Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Last Updated:July 11, 2023Recruiting
Condition(s):Prostate CancerLast Updated:August 7, 2023Recruiting
Condition(s):MalignancyLast Updated:March 9, 2023Recruiting
Condition(s):Glioma; Astrocytoma; Anaplastic Astrocytoma; Oligodendroglioma; Glioblastoma MultiformeLast Updated:February 8, 2024Not yet recruiting
Condition(s):Prostate CancerLast Updated:March 27, 2024Recruiting
Condition(s):Prostate AdenocarcinomaLast Updated:January 3, 2024Recruiting
Condition(s):Thyroid Gland CarcinomaLast Updated:June 29, 2021Terminated
Condition(s):Prostatic NeoplasmsLast Updated:June 9, 2023Recruiting
Condition(s):Castration-Resistant Prostatic CancerLast Updated:February 26, 2024Available
Condition(s):Prostate CancerLast Updated:October 30, 2023Enrolling by invitation
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.